Stay updated with breaking news from Polypid Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
PolyPid Ltd. (NASDAQ:PYPD – Get Free Report) was the recipient of a significant decline in short interest in November. As of November 15th, there was short interest totalling 1,000 shares, a decline of 68.8% from the October 31st total of 3,200 shares. Currently, 0.1% of the company’s shares are short sold. Based on an average […]
Total of 20 Centers Currently Open with Approximately 40 Expected by End of 2023 in SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Preventio...
PETACH TIKVA, Israel, Oct. 09, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company...
Safety Profile of D-PLEX100 and PLEX Platform Shown in Juvenile Animals for the First Time Results Could Support Clinical Evaluation of D-PLEX100 in Pediatric Population PETACH TIKVA, Israel, Oct. 04, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced the publication of positive preclinical results demonstrating, for the first time, the safety profile of D-PLEX100 and the PLEX tech
PolyPid Ltd. (NASDAQ:PYPD – Get Free Report) was the target of a significant drop in short interest in September. As of September 15th, there was short interest totalling 1,500 shares, a drop of 88.7% from the August 31st total of 13,300 shares. Based on an average trading volume of 5,500 shares, the short-interest ratio is […]